IDEXX Laboratories, Inc. $IDXX Shares Acquired by Franklin Street Advisors Inc. NC

Franklin Street Advisors Inc. NC increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 40,183 shares of the company’s stock after purchasing an additional 3,469 shares during the period. IDEXX Laboratories accounts for about 1.6% of Franklin Street Advisors Inc. NC’s holdings, making the stock its 21st biggest holding. Franklin Street Advisors Inc. NC owned approximately 0.05% of IDEXX Laboratories worth $27,185,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Virtus Advisers LLC acquired a new stake in IDEXX Laboratories during the third quarter worth about $26,000. Park Place Capital Corp acquired a new stake in IDEXX Laboratories during the fourth quarter worth about $29,000. J.Safra Asset Management Corp acquired a new stake in IDEXX Laboratories during the third quarter worth about $31,000. Armstrong Advisory Group Inc. increased its position in IDEXX Laboratories by 55.9% during the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after purchasing an additional 19 shares during the last quarter. Finally, Salomon & Ludwin LLC acquired a new stake in IDEXX Laboratories during the third quarter worth about $35,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Up 3.0%

Shares of IDXX stock opened at $591.84 on Thursday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The firm has a market cap of $47.01 billion, a PE ratio of 45.28, a price-to-earnings-growth ratio of 3.46 and a beta of 1.72. The company has a 50-day moving average of $611.40 and a two-hundred day moving average of $657.72. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.15. The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Michael G. Erickson sold 5,371 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the transaction, the executive vice president owned 12,693 shares of the company’s stock, valued at approximately $7,963,334.34. This trade represents a 29.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP George Fennell sold 11,345 shares of the firm’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the transaction, the executive vice president directly owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. The trade was a 53.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 45,957 shares of company stock valued at $29,862,109. 0.98% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several recent analyst reports. Wall Street Zen cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Barclays cut their price objective on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. BTIG Research cut their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Piper Sandler cut their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. Finally, UBS Group lowered their target price on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research note on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $772.22.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.